BW Energy Limited (6BW) Chart

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

DP Poland PLC (AIM:DPP) CEO Nils Gornall talked with Proactive about the company’s acquisition of Pizzeria 105 in Poland for £8.5 million — a key step in its strategy to transition towards a franchise-led business model. Gornall explained that DP Poland is the master franchisee of Domino’s Pizza in both Poland and Croatia, and this latest acquisition boosts the company’s franchised store percentage from just 8% three years ago to over 50% today. “The best Domino’s businesses around the world are franchisee-led. That's where we need to be,” he said. Pizzeria 105 is the fourth-largest pizza chain in Poland, with 90 franchised stores. Gornall emphasised how this acquisition aligns with DP Poland’s strategy, highlighting the opportunity to bring Domino’s global brand power and systems to a well-established local operator. “We have the tools to help the franchisees really take it to that next level,” he said. Looking ahead, Gornall noted the goal of rebranding all Pizzeria 105 stores to Domino’s within 24 months, with a target of reaching 200 fully branded Domino’s outlets by late 2026 or early 2027. The transaction also adds more than 80 franchise business owners to DP Poland’s ecosystem and supports a shift toward selling down corporate-owned stores. He said the key focus now is rebranding and driving sales performance with Domino’s marketing and operational capabilities. The long-term ambition is to move from 50% to 90% franchise ownership. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #DPoland #DominosPizza #FranchiseGrowth #PizzaMarket #PolandBusiness #DominosPoland #NilsGornall #FoodIndustry #FranchiseStrategy #Pizzeria105 #CompanyAcquisition #InvestingInPoland #FastFoodBusiness

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to discuss the company’s impressive financial and operational performance for the fourth quarter and full year ended December 31, 2024. The company reported a remarkable 62% increase in fourth-quarter revenues, reaching $7.3 million, while full-year revenue surged by 99% year-over-year to $25.2 million, surpassing prior guidance. A key driver of this growth has been the continued expansion of VINIA®, BioHarvest’s flagship product line. As of February 2025, total VINIA® subscribers exceeded 50,000, contributing to a cumulative revenue milestone of $50 million since launch. Building on this momentum, the company successfully introduced its VINIA SuperFood Tea line, leveraging its "VINIA Inside" strategy following the successful launch of VINIA SuperFood Coffee in December 2023. Beyond its financial success, BioHarvest achieved several strategic milestones in 2024. Sobel highlighted a groundbreaking partnership with Tate & Lyle to develop plant-based sweeteners, further validating BioHarvest’s innovative Botanical Synthesis platform. Additionally, the company expanded its VINIA product portfolio and completed a successful uplisting to the Nasdaq Global Market, strengthening its position for accelerated growth and operational efficiency in 2025. With a strong foundation and continued product innovation, BioHarvest Sciences is poised to drive further market expansion and deliver sustained shareholder value in the coming year. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Itaconix PLC (AIM:ITX, OTCQB:ITXXF) CEO John Shaw joined Steve Darling from Proactive to provide an update on the company’s progress following its strategic restructuring and to discuss what lies ahead for 2025. Shaw highlighted that the company ended 2024 with strong momentum, achieving nearly $3.7 million in revenue in the second half, marking one of its highest-ever earnings periods. The restructuring initiative focused on enhancing profitability, with a significant emphasis on reshaping the customer base. Shaw noted, “We actually increased our gross profit margin from about 31% to almost 35% last year.” Despite experiencing lower revenue in some areas, the company was able to maintain steady gross profits due to its emphasis on margin improvement. Shaw also discussed significant product developments, including the launch of Itaconix TSI 422, a new detergent ingredient that is gaining traction in North America and Europe. He further explained how the SPARX program, introduced in October, is helping accelerate customer collaboration in key product categories, positioning the company for continued growth. In addition to product development, the company has made strategic investments in its operations, marketing, and regulatory capabilities to support its growth trajectory. Shaw expressed confidence in the company’s production team and infrastructure, stating, “We really have everything in place we need right now to have a great run over the next 24 months.” While tariffs remain a consideration, Shaw believes any impacts will be manageable, and in some cases, could even be beneficial to the company. #proactiveinvestors #itaconixplc #aim #itx #otcqb #itxxf #SustainableChemicals #CleanTech #TSI422 #SPARXProgram #SpecialtyChemicals #JohnShaw #InvestorUpdates #ProactiveInvestors #GreenChemistry #DetergentInnovation #GrossProfitMargins #RestructuringSuccess